- News Releases
The “on-off” switches of genes that occur early in the development of prostate cancer could be used as biomarkers to detect the disease months or even years earlier. This Mayo Clinic study found these biomarkers — known as DNA methylation profiles — also can predict if the cancer is going to recur and if that recurrence will remain localized to the prostate or, instead, spread to other organs.
The study is the first to capture the methylation changes that occur across the entire human genome in prostate cancer. It's published in the journal Clinical Cancer Research.
Soundbites from senior author, Krishna Donkena, Ph.D., available in downloads above.
Expert title for broadcast cg:
Dr. Krishna Donkena, Mayo Clinic Molecular Biologist
Click here for entire release.
Shortly before Thanksgiving 2021, Jerry Haines, a part-time farmer and retired butter and cheesemaker, was helping another farmer with fall chores. He felt good but ...
May is Bladder Cancer Awareness Month, which makes this a good time to learn about the risk factors for bladder cancer and what you can do ...
May is Brain Cancer Awareness Month, which makes this a good time to learn about metastatic brain cancer. Overall, the chance that a person will develop ...